Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C plus V): a pooled analysis

被引：0

作者：

Lewis, K. ^{[1
]}

Larkin, J. ^{[2
]}

Ribas, A. ^{[3
]}

Flaherty, K. T. ^{[4
]}

McArthur, G. A. ^{[5
]}

Ascierto, P. A. ^{[6
]}

Dreno, B. ^{[7
]}

McKenna, E. ^{[8
]}

Zhu, Q. ^{[9
]}

Mun, Y. ^{[8
]}

Hauschild, A. ^{[10
]}

机构：

[1] Univ Colorado, Comprehens Canc Ctr, Med, Aurora, CO USA

[2] Royal Marsden Hosp NHS Fdn Trust, Oncol, London, England

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA

[4] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA

[5] Peter MacCallum Canc Ctr, Dept Med Oncol, East Melbourne, Australia

[6] Ist Nazl Tumori Fdn Pascale, Canc Immunotherapy & Innovat Therapy Unit, Melanoma, Naples, Italy

[7] Nantes Univ, Dermatol, Nantes, France

[8] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA

[9] Genentech Inc, Oncol, San Francisco, CA 94080 USA

[10] Univ Hosp Schleswig Holstein, Dermatol, Kiel, Germany

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1241P

引用

页数：1

共 50 条

[21] Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma
Haydon, Andrew
Dummer, Reinhard
Flaherty, Keith
Robert, Caroline
Arance, Ana M.
de Groot, Jan Willem
Garbe, Clause
Gogas, Helen
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
Zohren, Fabien
Atkinson, Victoria
Millward, Michael
Hill, Andrew
Edwards, Michelle L.
Ascierto, Paolo A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 123 - 124
[22] Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.
Dummer, Reinhard
Flaherty, Keith
Robert, Caroline
Arance, Ana Maria
De Groot, Jan Willem
Garbe, Claus
Gogas, Helen
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
Pickard, Michael D.
Zohren, Fabian
Edwards, Michelle L.
Ascierto, Paolo Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] BUDGET IMPACT MODEL OF COBIMETINIB IN COMBINATION WITH VEMURAFENIB FOR PREVIOUSLY UNTREATED BRAF V600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
Kyriopoulos, D.
Athanasakis, K.
Akratos, A.
Theodoropoulou, F.
Caporis, X.
Kyriopoulos, J.
VALUE IN HEALTH, 2017, 20 (09) : A423 - A423
[24] Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Ascierto, Paolo A.
Dummer, Reinhard
Gogas, Helen J.
Flaherty, Keith T.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
de Groot, Jan Willem B.
Loquai, Carmen
Gollerkeri, Ashwin
Pickard, Michael D.
Robert, Caroline
EUROPEAN JOURNAL OF CANCER, 2020, 126 : 33 - 44
[25] Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
Larkin, James M. G.
Ribas, Antoni
Flaherty, Keith
McArthur, Grant A.
Ascierto, Paolo Antonio
Dreno, Brigitte
Lewis, Karl D.
Chapman, Paul B.
Mckenna, Edward Francis
Zhu, Qian
Mun, Yong
Hauschild, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
Lopez-Martin, Jose A.
Berrocal, Alfonso
Gonzalez-Cao, Maria
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO plus BINI): Comparing real-world vs clinical trial data
In, G. K.
Chen, K.
Sajeev, G.
Simpson, R.
Kalia, S.
Christensen, D.
Liu, D.
Rezai, N.
di Pietro, A.
Signorovitch, J.
ANNALS OF ONCOLOGY, 2023, 34 : S673 - S673
[28] Cobimetinib plus vemurafenib (C plus V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study
Meric-Bernstam, Funda
Rothe, Michael
Garrett-Mayer, Elizabeth
Gutierrez, Rodolfo
Ahn, Eugene R.
Cannon, Timothy Lewis
Powell, Steven Francis
Krauss, John C.
Reynolds, Christopher M.
Von Mehren, Margaret
Behl, Deepti
Calfa, Carmen Julia
Duvivier, Herbert Leon
Kaplan, Henry G.
Livingston, Michael B.
Sharma, Manish
Urba, Walter John
O'Lone, Raegan
Halabi, Susan
Schilsky, Richard L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[29] COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D plus T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)
Grob, J. J.
Amonkar, M.
Karaszewska, B.
Schachter, J.
Dummer, R.
Mackiewicz, A.
Stroiakovski, D.
Drucis, K.
Grange, F.
Chiarion-Sileni, V.
Rutkowski, P.
Lichinitser, M.
Levchenko, E.
Wolter, P.
Hauschild, A.
Long, G. V.
Sun, P.
McDowell, D. O.
Mookerjee, B.
Robert, C.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S682 - S683
[30] Identification of prognostic subgroups for overall survival in patients (pts) with BRAFV600-mutated metastatic melanoma treated with vemurafenib ± cobimetinib: a pooled exploratory analysis of the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies
Hauschild, A.
Larkin, J.
Ribas, A.
Dreno, B.
Flaherty, K. T.
Ascierto, P. A.
Lewis, K. D.
Mckenna, E.
Zhu, Q.
Mun, Y.
Mcarthur, G. A.
MELANOMA RESEARCH, 2016, 26 : E1 - E2

← 1 2 3 4 5 →